SCHEDULE: ADAR1 Capital Discloses 6.3% Stake in Prothena

ADAR1 Capital Management, LLC and related entities have disclosed a passive beneficial ownership of 6.3% in Prothena Corporation Public Limited Company.

Summary

• ADAR1 Capital Management, LLC, along with ADAR1 Capital Management GP, LLC and Daniel Schneeberger, have filed a Schedule 13G disclosing their beneficial ownership in Prothena Corporation Public Limited Company.
• As of June 30, 2025, ADAR1 Capital Management, LLC beneficially owns 3,375,009 ordinary shares, representing 6.3% of Prothena's outstanding shares.
• This ownership includes 2,892,995 shares held by ADAR1 Partners, LP and 482,014 shares held by Spearhead Insurance Solutions IDF, LLC.
• ADAR1 Capital Management GP, LLC, as the general partner of ADAR1 Partners, LP, beneficially owns 2,892,995 shares, equating to 5.4% of the class.
• Daniel Schneeberger, as the manager of both ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, is deemed to indirectly beneficially own 2,892,995 shares, also representing 5.4% of the class.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Prothena Corporation Public Limited Company.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a 13G is a factual disclosure, a significant passive stake by an institutional investor can be seen as a vote of confidence in the company's value, without implying any immediate operational changes or financial impact.

Positives

• A significant institutional investor has taken a passive stake, indicating confidence in the company's long-term prospects without seeking control.
• The investment is stated to be in the ordinary course of business, suggesting a standard portfolio allocation rather than an activist position.

Negatives

• The filing does not contain information that would be considered negative, as it is a standard disclosure of passive ownership.

Risks

• The filing itself does not introduce new risks but rather discloses a significant ownership stake. The inherent risks of investing in Prothena Corporation Public Limited Company, such as market volatility, industry-specific challenges, and company-specific operational risks, remain.

Future Outlook

The filing is a disclosure of beneficial ownership and does not provide any forward-looking statements or guidance regarding the issuer's future performance or strategic direction.

Industry Context

This filing reflects a significant passive investment by an institutional fund in Prothena Corporation, a company operating in the biotechnology and pharmaceutical sector. Such disclosures are common as funds adjust their portfolios, and this particular filing indicates a belief in the long-term value of Prothena's shares without an intent to influence management or strategy.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant ownership stakes, which can influence market perception and liquidity. The passive nature of the investment suggests no immediate changes to corporate control or strategy.
• Management: Awareness of a significant passive investor, but no direct impact on day-to-day operations or strategic decisions is implied by this filing.

Key Dates

Keywords

Prothena Corporation, ADAR1 Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Ordinary Shares, Biotechnology, Pharmaceuticals, Investment, Stake